Allogene Therapeutics Presents Preclinical Data On Next Generation Cloak And Dagger Technologies At The Society For Immunotherapy Of Cancer Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Allogene Therapeutics, Inc. (NASDAQ:ALLO) presented data on its next generation Cloak and Dagger technologies at the Society for Immunotherapy of Cancer Annual Meeting. These technologies are designed to enhance the performance of AlloCAR T cell candidates and control immune rejection. The Cloak technology prevents AlloCAR T cells from being recognized by host T cells, while the Dagger technology arms AlloCAR T cells with a CD70 CAR designed to recognize and deplete CD70-positive host immune cells. The Dagger technology is a feature of ALLO-316, currently being investigated in a Phase 1 study for solid tumors.
November 03, 2023 | 4:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Allogene Therapeutics presented promising data on its Cloak and Dagger technologies, which could enhance the performance of AlloCAR T cell candidates. This could potentially boost the company's reputation in the biotech industry and increase investor interest.
The presentation of promising data on Allogene's Cloak and Dagger technologies could potentially increase investor interest in the company. These technologies are designed to enhance the performance of AlloCAR T cell candidates, which could be a significant advancement in the field of cancer immunotherapy. This could potentially lead to increased demand for the company's stock, leading to a short-term increase in its price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100